4000点拉锯战，制药板块缘何低调逆袭？基金经理火线解读！

Core Viewpoint - The pharmaceutical sector demonstrates defensive strength amid market volatility, with the drug ETF (562050) showing resilience and outperforming the broader market [1][3]. Group 1: Market Performance - On November 14, the Shanghai Composite Index fell by 0.97% to close at 3990.39 points, while the ChiNext Index dropped by 2.82%, erasing previous gains [1]. - The drug ETF (562050) recorded a weekly increase of 3.33%, significantly outperforming the market, where the Shanghai Composite Index declined by 0.18% and the ChiNext Index fell by 3.01% [3]. Group 2: Sector Analysis - Since September, the pharmaceutical sector has experienced over a 10% decline from its peak, but recent trends indicate a recovery, with nearly 2.5 billion yuan (approximately 25 million) invested in pharmaceutical ETFs this week [3]. - The pharmaceutical industry is characterized as a necessity sector with substantial future market potential, driven by an aging population and increasing demand for chronic disease treatments [6]. Group 3: Investment Insights - The fund manager of the drug ETF highlighted that the end of the year is typically a peak season for mergers and acquisitions in the U.S. biopharmaceutical sector, with favorable conditions for innovative drugs expected to continue [5]. - The third-quarter reports indicate a recovery in the innovative drug sector, with several companies returning to profitability, suggesting a shift from research investment to commercialization [6]. - The drug ETF (562050) tracks 50 leading pharmaceutical companies, with a focus on innovative drugs and a 25% allocation to traditional Chinese medicine, which offers a relatively high dividend yield and stable performance [6].